Cargando…

A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses

The tremendous global impact of the current SARS-CoV-2 pandemic, as well as other current and recent outbreaks of (re)emerging viruses, emphasize the need for fast-track development of effective vaccines. Yellow fever virus 17D (YF17D) is a live-attenuated virus vaccine with an impressive efficacy r...

Descripción completa

Detalles Bibliográficos
Autores principales: Oreshkova, Nadia, Myeni, Sebenzile K., Mishra, Niraj, Albulescu, Irina C., Dalebout, Tim J., Snijder, Eric J., Bredenbeek, Peter J., Dallmeier, Kai, Kikkert, Marjolein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704410/
https://www.ncbi.nlm.nih.gov/pubmed/34960238
http://dx.doi.org/10.3390/vaccines9121492
_version_ 1784621701046206464
author Oreshkova, Nadia
Myeni, Sebenzile K.
Mishra, Niraj
Albulescu, Irina C.
Dalebout, Tim J.
Snijder, Eric J.
Bredenbeek, Peter J.
Dallmeier, Kai
Kikkert, Marjolein
author_facet Oreshkova, Nadia
Myeni, Sebenzile K.
Mishra, Niraj
Albulescu, Irina C.
Dalebout, Tim J.
Snijder, Eric J.
Bredenbeek, Peter J.
Dallmeier, Kai
Kikkert, Marjolein
author_sort Oreshkova, Nadia
collection PubMed
description The tremendous global impact of the current SARS-CoV-2 pandemic, as well as other current and recent outbreaks of (re)emerging viruses, emphasize the need for fast-track development of effective vaccines. Yellow fever virus 17D (YF17D) is a live-attenuated virus vaccine with an impressive efficacy record in humans, and therefore, it is a very attractive platform for the development of novel chimeric vaccines against various pathogens. In the present study, we generated a YF17D-based replicon vaccine platform by replacing the prM and E surface proteins of YF17D with antigenic subdomains from the spike (S) proteins of three different betacoronaviruses: MERS-CoV, SARS-CoV and MHV. The prM and E proteins were provided in trans for the packaging of these RNA replicons into single-round infectious particles capable of expressing coronavirus antigens in infected cells. YF17D replicon particles expressing the S1 regions of the MERS-CoV and SARS-CoV spike proteins were immunogenic in mice and elicited (neutralizing) antibody responses against both the YF17D vector and the coronavirus inserts. Thus, YF17D replicon-based vaccines, and their potential DNA- or mRNA-based derivatives, may constitute a promising and particularly safe vaccine platform for current and future emerging coronaviruses.
format Online
Article
Text
id pubmed-8704410
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87044102021-12-25 A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses Oreshkova, Nadia Myeni, Sebenzile K. Mishra, Niraj Albulescu, Irina C. Dalebout, Tim J. Snijder, Eric J. Bredenbeek, Peter J. Dallmeier, Kai Kikkert, Marjolein Vaccines (Basel) Article The tremendous global impact of the current SARS-CoV-2 pandemic, as well as other current and recent outbreaks of (re)emerging viruses, emphasize the need for fast-track development of effective vaccines. Yellow fever virus 17D (YF17D) is a live-attenuated virus vaccine with an impressive efficacy record in humans, and therefore, it is a very attractive platform for the development of novel chimeric vaccines against various pathogens. In the present study, we generated a YF17D-based replicon vaccine platform by replacing the prM and E surface proteins of YF17D with antigenic subdomains from the spike (S) proteins of three different betacoronaviruses: MERS-CoV, SARS-CoV and MHV. The prM and E proteins were provided in trans for the packaging of these RNA replicons into single-round infectious particles capable of expressing coronavirus antigens in infected cells. YF17D replicon particles expressing the S1 regions of the MERS-CoV and SARS-CoV spike proteins were immunogenic in mice and elicited (neutralizing) antibody responses against both the YF17D vector and the coronavirus inserts. Thus, YF17D replicon-based vaccines, and their potential DNA- or mRNA-based derivatives, may constitute a promising and particularly safe vaccine platform for current and future emerging coronaviruses. MDPI 2021-12-16 /pmc/articles/PMC8704410/ /pubmed/34960238 http://dx.doi.org/10.3390/vaccines9121492 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Oreshkova, Nadia
Myeni, Sebenzile K.
Mishra, Niraj
Albulescu, Irina C.
Dalebout, Tim J.
Snijder, Eric J.
Bredenbeek, Peter J.
Dallmeier, Kai
Kikkert, Marjolein
A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
title A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
title_full A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
title_fullStr A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
title_full_unstemmed A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
title_short A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
title_sort yellow fever 17d virus replicon-based vaccine platform for emerging coronaviruses
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704410/
https://www.ncbi.nlm.nih.gov/pubmed/34960238
http://dx.doi.org/10.3390/vaccines9121492
work_keys_str_mv AT oreshkovanadia ayellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT myenisebenzilek ayellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT mishraniraj ayellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT albulescuirinac ayellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT dalebouttimj ayellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT snijderericj ayellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT bredenbeekpeterj ayellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT dallmeierkai ayellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT kikkertmarjolein ayellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT oreshkovanadia yellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT myenisebenzilek yellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT mishraniraj yellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT albulescuirinac yellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT dalebouttimj yellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT snijderericj yellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT bredenbeekpeterj yellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT dallmeierkai yellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses
AT kikkertmarjolein yellowfever17dvirusrepliconbasedvaccineplatformforemergingcoronaviruses